Anzeige
Meldung des Tages: Gold auf 6.300 USD? Diese Aktie könnte der geheime Hebel sein

Soleno Therapeutics News

Aktie
WKN:  A3DS0P ISIN:  US8342033094 US-Symbol:  SLNO Branche:  Biotechnologie Land:  USA
44,20 €
-0,26 €
-0,58%
11:13:21 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,86 Mrd. €
Streubesitz
-
KGV
-11,24
Index-Zuordnung
-

Soleno Therapeutics News

14.04.26 - PR Newswire
SLNO Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Soleno Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
SLNO Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Soleno Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm PR Newswire
13.04.26 - PR Newswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman PR Newswire
13.04.26 - PR Newswire
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO PR Newswire
13.04.26 - PR Newswire
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
12.04.26 - PR Newswire
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 PR Newswire
10.04.26 - PR Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline PR ...
10.04.26 - PR Newswire
Are SLNO, THR, AFBI Obtaining Fair Deals for their Shareholders?
Are SLNO, THR, AFBI Obtaining Fair Deals for their Shareholders? PR Newswire
09.04.26 - PR Newswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman PR Newswire
09.04.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLNO
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLNO ...
08.04.26 - PR Newswire
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit PR Newswire
08.04.26 - PR Newswire
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
07.04.26 - PR Newswire
SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman
SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman PR Newswire
07.04.26 - PR Newswire
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm PR Newswire
06.04.26 - PR Newswire
Are SLNO, FORA, AFBI, MKC Obtaining Fair Deals for their Shareholders?
Are SLNO, FORA, AFBI, MKC Obtaining Fair Deals for their Shareholders? PR Newswire
06.04.26 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) PR Newswire
06.04.26 - PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders PR Newswire
06.04.26 - PR Newswire
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio PR Newswire
06.04.26 - PR Newswire
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO PR Newswire
06.04.26 - PR Newswire
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
05.04.26 - PR Newswire
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire

Newssuche

Videos

newspaper
07.04.26 +0,66%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »